Aadi Bioscience Inc reports results for the quarter ended in September - Earnings Summary

Whitehawk Therapeutics

09/11/2022 14:33

* Aadi Bioscience Inc  AADI.OQ  reported a quarterly
adjusted loss
of 68 cents​​ per share for the quarter ended in September. The
mean expectation of five analysts for the quarter was for a loss
of 74 cents per share.
    * Revenue was $4.25 million​; analysts expected $3.77
million. 
    * Aadi Bioscience Inc's reported EPS for the quarter was a
loss
of 68 cents​.
    * The mean earnings estimate of analysts had risen by
about 2.9%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Aadi Bioscience Inc shares had fallen by 7.7% this
quarter and
lost 46.0% so far this year.
    * The company reported a quarterly loss of $14.47 million.
    * Wall Street's median 12-month price target for Aadi
Bioscience
Inc is $46.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
9 at 02:33 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.74          -0.68          Beat
 Jun. 30 2022      -0.75          -0.87          Missed
 Mar. 31 2022      -0.71          -0.66          Beat
 Dec. 31 2021      -0.98          -0.77          Beat